Can you list diseases targeted by apotex's ruxolitinib?

What diseases does Apotex’s ruxolitinib target?

Apotex’s ruxolitinib is used to treat two main disease areas:

Bone marrow disorders (myelofibrosis and related conditions)

Ruxolitinib (marketed by Apotex in applicable markets) is targeted at:
- Myelofibrosis, including primary myelofibrosis
- Post–polycythemia vera myelofibrosis
- Post–essential thrombocythemia myelofibrosis [1]

Blood cancers involving the JAK pathway (polycythemia vera)

Ruxolitinib is also targeted at:
- Polycythemia vera in patients who are resistant to or intolerant of hydroxyurea [1]

Which indications are most commonly listed for ruxolitinib products like Apotex’s?

When people search for “diseases targeted by ruxolitinib,” the indications most often include:
- Myelofibrosis (as primary or post-PV/post-ET)
- Polycythemia vera after hydroxyurea intolerance or resistance [1]

Are these uses consistent across ruxolitinib brands and manufacturers?

The underlying ruxolitinib indications are driven by the drug’s regulatory labeling (not just the manufacturer). Apotex’s ruxolitinib targets the same labeled disease categories listed above for ruxolitinib products [1].

Source

[1] https://www.drugs.com/ (search “ruxolitinib indications myelofibrosis polycythemia vera”)